THE LATEST | CANADABloomberg: Moderna Inc.’s shares fell in late trading after US regulators refused to review its novel mRNA flu vaccine, dealing a major blow to the company as it seeks more products beyond its Covid shot…
FDA won’t review Moderna application for first mRNA-based flu vaccine
Subscribe
Login
0 Comments
Oldest